Is PD-L1 inhibition good enough for 1L cis-
ineligible urothelial cancer?
1. De Santis et al. J Clin Oncol 2012; 2. Bellmunt et al. ESMO 2016; 3. Balar et al. ESMO 2016
•
ORR=41.2% (CR was 3.0%)
•
ORR=23.0% (CR was 9.0%)
IMvigor210 Cohort 1
2
EORTC Study 30986
1
Overall survival
(
%
)
100
80
60
40
20
0
Time (years)
3
4
5
1
2
0
6
7
Median OS
GC: 9.3 months
M-CAVI: 8.1 months
12-month OS rate
GC: 39%
M-CAVI: N/A
GC (n=119)
M-CAVI (n=119)
KEYNOTE-052
3
0
0
20
40
60
80
100
4
8
12
Time (months)
Overall survival (%)
16
20
24
Subgroup
All (N=119)
IC0/1 (n=87)
IC2/3 (n=32)
Median OS (95% Cl)
15.9 mo (10.4, NE)
19.1 mo (9.8, NE)
12.3 mo (6.0, NE)
•
ORR=24.0% (CR was 6.0%)
Awaiting OS data
•
Median follow-up duration:
–
8 months (range, 0.1–13.4)
•
Median time to response:
–
2.0 months (range, 1.9–4.8)
•
Median duration of response:
–
Not reached (range, 1.4+ to 9.8+
months)
–
Duration of response
≥6 months: 83%
